Drug Type Small molecule drug |
Synonyms |
Target |
Mechanism DPP-4 inhibitors(Dipeptidyl peptidase IV inhibitors), SGLT2 inhibitors(Sodium/glucose cotransporter 2 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC24H35ClO9 |
InChIKeyGOADIQFWSVMMRJ-UPGAGZFNSA-N |
CAS Registry960404-48-2 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Diabetes Mellitus | Phase 3 | KR | 01 Jun 2023 | |
Diabetes Mellitus, Type 2 | Phase 3 | KR | 27 Apr 2021 |
Phase 3 | 235 | Dapagliflozin/Linagliptin FDC (AJU-A51) 10/5 mg/day | (xcqgslxogy) = xaffdrevuy crnmjfkdop (qatvkpbxnh, 0.61) View more | Positive | 07 Oct 2024 | ||
Linagliptin 5 mg plus Placebo | (xcqgslxogy) = nojrmixsjb crnmjfkdop (qatvkpbxnh, 0.94) View more | ||||||
Phase 3 | 232 | rxkrufckyu(mpjiwiktfc) = ajnjricjnx tvzfigfchj (ahhthwdjkv, ±2.29) View more | Positive | 14 Jun 2024 | |||
xqbyiqzbep(qzrdnfxyrx) = jhcoazuzra sjormllmpj (xbapzfwxgm ) |